CD274 and neoplasm: Of the 3 molecules developed, only relatlimab combined with nivolumab has been approved as a first-line treatment by both the U.S. Food and Drug Administration (73) and the European Medicine Agency, which has restricted the indication to patients with tumor cell PD-L1 expression < 1% (74).